Cost-effectiveness acceptability curves - facts, fallacies and frequently asked questions

被引:690
作者
Fenwick, E
O'Brien, BJ
Briggs, A
机构
[1] St Josephs Hosp, Ctr Evaluat Med, Hamilton, ON, Canada
[2] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada
[3] Univ Oxford, Hlth Econ Res Ctr, Oxford, England
关键词
cost-effectiveness acceptability curves; uncertainty; cost-effectiveness planes; decision-making;
D O I
10.1002/hec.903
中图分类号
F [经济];
学科分类号
02 ;
摘要
Cost-effectiveness acceptability curves (CEACs) have been widely adopted as a method to quantify and graphically represent uncertainty in economic evaluation studies of health-care technologies. However, there remain some common fallacies regarding the nature and shape of CEACs that largely result from the 'textbook' illustration of the CEAC. This 'textbook' CEAC shows a smooth curve starting at probability 0, with an asymptote to I for higher money values of the health outcome (lambda). But this familiar 'ogive' shape which makes the 'textbook' CEAC look like a cumulative distribution function is just one special case of the CEAC. The reality is that the CEAC can take many shapes and turns because it is a graphic transformation from the cost-effectiveness plane, where the joint density of incremental costs and effects may 'straddle' quadrants with attendant discontinuities and asymptotes. In fact CEACs: (i) do not have to cut the y-axis at 0; (ii) do not have to asymptote to 1; (iii) are not always monotonically increasing in lambda and (iv) do not represent cumulative distribution functions (cdfs). Within this paper we present a 'gallery' of CEACs in order to identify the fallacies and illustrate the facts surrounding the CEAC. The aim of the paper is to serve as a reference tool to accompany the increased use of CEACs within major medical journals. Copyright (C) 2004 John Wiley Sons, Ltd.
引用
收藏
页码:405 / 415
页数:11
相关论文
共 40 条
[1]  
Ashton HA, 2002, BMJ-BRIT MED J, V325, P1135
[2]   THE CE PLANE - A GRAPHIC REPRESENTATION OF COST-EFFECTIVENESS [J].
BLACK, WC .
MEDICAL DECISION MAKING, 1990, 10 (03) :212-214
[3]   Meta-analysis of data on costs from trials of counselling in primary care: using individual patient data to overcome sample size limitations in economic analyses [J].
Bower, P ;
Byford, S ;
Barber, J ;
Beecham, J ;
Simpson, S ;
Friedli, K ;
Corney, R ;
King, M ;
Harvey, I .
BRITISH MEDICAL JOURNAL, 2003, 326 (7401) :1247-1250
[4]  
BRIGGA AH, 1999, HLTH TECHNOL ASSESS, V3
[5]  
Briggs A, 1998, HEALTH ECON, V7, P723, DOI 10.1002/(SICI)1099-1050(199812)7:8<723::AID-HEC392>3.3.CO
[6]  
2-F
[7]  
Briggs AH, 1999, HEALTH ECON, V8, P257, DOI 10.1002/(SICI)1099-1050(199905)8:3<257::AID-HEC427>3.0.CO
[8]  
2-E
[9]   Cost-effectiveness of brief cognitive behaviour therapy versus treatment as usual in recurrent deliberate self-harm:: a decision-making approach [J].
Byford, S ;
Knapp, M ;
Greenshields, J ;
Ukoumunne, OC ;
Jones, V ;
Thompson, S ;
Tyrer, P ;
Schmidt, U ;
Davidson, K .
PSYCHOLOGICAL MEDICINE, 2003, 33 (06) :977-986
[10]   Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis [J].
Chilcott, J ;
McCabe, C ;
Tappenden, P ;
O'Hagan, A ;
Cooper, NJ ;
Abrams, K ;
Claxton, K .
BRITISH MEDICAL JOURNAL, 2003, 326 (7388) :522-525